Abstract:Objective: Lower extremity computed tomography angiography (CTA) is frequently used for anatomic assessment of lower extremity peripheral arterial disease. When lower extremity bypass is planned, duplex ultrasound (DUS) is routinely obtained to evaluate the great saphenous vein (GSV) for use as conduit. Although GSV can be visualized on CTA images, diameter assessment is not routinely included in formal study interpretation. We hypothesized that CTA images could be used to measure GSV diameters and that CTA-based diameters would correlate with measurements obtained using DUS. Methods: Consecutive patients undergoing lower extremity arterial bypass who were evaluated preoperatively with both CTA and DUS vein mapping were identified at a single hospital. Minimum aboveand below-knee GSV diameters were measured from electronically archived CTA images by two independent observers. CTAs were performed using standard arterial phase protocol without additional venous phase imaging. Between-observer reproducibility of CTA-based diameter measurements was evaluated using intraclass correlation coefficients. Correlation between CTA and DUS-based GSV diameters was evaluated with Spearman correlation coefficients. CTA diameter cut-points for identification of adequate GSV bypass conduit, defined as DUS-based minimum GSV diameter > 3 mm, were determined using receiver-operating characteristic curves. Results: Sixty-three lower extremities were evaluated in 36 patients. In the absence of previous surgical removal, GSV was visible on all CTAs reviewed. No instances of GSV thrombosis were identified on DUS. Minimum DUS-based above-knee GSV diameter was 2.9 0.1 mm (range, 1.4-4.6 mm), and mean below-knee diameter was 2.6 0.1 mm (range, 1.3-4.0 mm). When GSV was visible and exceeded the minimum diameter threshold for CTA measurement, correlation between CTAand DUS-based diameters was both positive and highly significant ( 0.595; P < .0001). CTA-based diameters also had excellent reliability between observers (r [95% CI]: 0.88 [0.85-0.91]). For identification of adequate bypass conduit using CTA, above-knee GSV diameter > 3.9 mm was 67% sensitive and 73% specific; below-knee GSV diameter >3.0 mm was 75% sensitive and 84% specific. Conclusions: CTA-based GSV diameter measurements have good reproducibility and highly significant correlation with DUS-based diameters. CTA-based GSV diameter is a specific but relatively insensitive indicator of adequate bypass conduit. When CTA-based diameters indicate inadequate GSV bypass conduit, confirmatory DUS vein mapping is warranted. Confirmatory DUS vein mapping may be unnecessary when adequate vein diameter is identified on CTA. (J Vasc Surg 2013;57:50-5.)

Antitrypanosomal activity & docking studies of isolated constituents from the lichen Cetraria islandica: possibly multifunctional scaffolds.

Clinical characteristics and proteome modifications in two Charcot-Marie-Tooth families with the AARS1 Arg326Trp mutation

Alanyl-tRNA synthetase 1 (AARS1) gene mutation in a family with intermediate Charcot-Marie-Tooth neuropathy

Variants of aminoacyl-tRNA synthetase genes in Charcot-Marie-Tooth disease: A Korean cohort study

A previously unreported NARS1 variant causes dominant distal hereditary motor neuropathy in a French family

A missense, loss-of-function YARS1 variant in a patient with proximal-predominant motor neuropathy

Expanded phenotype of AARS1-related white matter disease

Characterization of a novel heterozygous variant in the histidyl‐tRNA synthetase gene associated with Charcot–Marie–Tooth disease type 2W

From the Southern Association for Vascular Surgery Computed tomography angiography-based evaluation of great saphenous vein conduit for lower extremity bypass

A familial form of Charcot-Marie-Tooth disease (type 2d) caused by a previously unreported variant in GARS1

Four pedigrees with aminoacyl-tRNA synthetase abnormalities

Comprehensive assessment of recessive, pathogenic AARS1 alleles in a humanized yeast model reveals loss-of-function and dominant-negative effects

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

Insights into phenotypic variability caused by GARS1 pathogenic variants

Recurrent acute liver failure in alanyl-tRNA synthetase-1 (AARS1) deficiency

Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

Aminoacyl-tRNA synthetase deficiencies in search of common themes

Bi‐allelic mutations in HARS1 severely impair histidyl‐tRNA synthetase expression and enzymatic activity causing a novel multisystem ataxic syndrome

Biallelic variants in ARHGAP19 cause a motor-predominant neuropathy with asymmetry and conduction slowing

Instability of the mitochondrial alanyl-tRNA synthetase underlies fatal infantile-onset cardiomyopathy

Glycyl-tRNA sequestration is a unifying mechanism underlying GARS1-associated peripheral neuropathy